Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...